Monday's announcement that Novartis (NYSE:NVS) will acquire Genoptix (Nasdaq:GXDX) offers an interesting lesson in how quickly things can change in the medical technology market. It was not so long ago that Genoptix was a hot idea and analysts treated it as an example of how the practice and business of medicine was changing. At that same time, Novartis was seen as a sluggish pharmaceutical company and a lagging part of the old guard.

IN PICTURES: 9 Simple Investing Ratios You Need To Know

More recently, though, Genoptix appeared to have hit a wall in its near-term growth and management seemed to have a nearly empty bag of tricks to change that. Novartis, though, has remade the investment community's vision of the company, with more credit being given to its attractive pipeline and growing generics business. To that end, Monday's deal gives Genoptix shareholders a decent exit strategy, while giving Novartis yet another growth option for the future. (For more, see The Latest Greatest Corporate Mergers And Acquisitions.)

The Terms of the Deal
Novartis announced that it will acquire Genoptix for $25 in cash, a 27% premium to Friday's price, but still a relative bargain on an EV/revenue or EV/EBITDA basis. Even acknowledging the low apparent valuation ratios on the deal, the terms were in line with the recent General Electric (NYSE:GE) acquisition of Clarient (a similar business) and reasonable relative to Genoptix's own near-term growth outlook. (For more, see Investment Valuation Ratios: Enterprise Value Multiple.)

What Novartis Is Getting
Genoptix is a specialized lab services provider that targets community-based oncologists and hematologists with its specialized diagnostic services in leukemias and lymphomas. In very simple terms, an oncologist will send a patient sample to Genoptix, who will perform a variety of advanced tests on it to determine whether the sample is cancerous (and if so, what type).

The business model is supposed to be something of a win-win for both parties. Community doctors do not have the resources (or the patient population) to justify the cost of advanced diagnostic equipment, nor the personnel to operate them. Moreover, Genoptix offers a more "hands on" customer service model that large reference labs like LabCorp (NYSE:LH) and Quest Diagnostics (NYSE:DGX) often find difficult (or too expensive) to match.

Unfortunately for Genoptix, the company had hit something of a wall. Although the company had about 10% of the bone marrow testing market and a customer base of over 1,300 oncologists, management seemed hard-pressed to find ways for the company to grow, and there was always the overhanging threat of more focused competition from LabCorp, Quest or Bio-Reference Laboratories (Nasdaq:BRLI).

Where Does Novartis Go Next?
In some respects, this could be a challenging deal for Novartis. Although there is more of a "high touch" sales aspect to pharmaceutical sales than many people realize, Genoptix nevertheless operates according to a much different model than the rest of Novartis's business. By the same token, it could be just one step in Novartis building a much larger and more comprehensive diagnostics enterprise. (For more, see A Checklist For Successful Medical Technology Investment.)

Diagnostics is arguably the only large high-growth/high-margin healthcare market where Novartis does not have much presence, and this deal could be the beginning of a bigger push. In buying Genoptix, Novartis is, at a minimum, acquiring state-of-the-art facilities and equipment, as well as highly trained technicians.

All of that could be leveraged with a larger suite of testing capabilities (either acquired or developed internally). There could be a natural synergy between cancer testing and a developer of cancer drugs - particularly as there seems to be an inexorable trend toward drugs that require advanced testing to identify those patients who will respond best. Although that thesis does not really argue for Novartis getting involved in the bidding for Beckman Coulter (NYSE:BEC), for instance, it could mean that Novartis is more of a player in molecular diagnostics deals in the future.

The Bottom Line
Novartis has not always been a company that has enjoyed the benefit of the doubt when it comes to Wall Street respecting or valuing the company's moves and strategies. Nevertheless, the stock still seems to be attractively priced, and the company offers investors a good growth outlook and one of the best pipelines among European biotechs without some of the risks that are bedeviling Sanofi-Aventis (NYSE:SNY), AstraZeneca (NYSE:AZN) or Roche (Nasdaq:RHHBY). Novartis has a long way to go before becoming any sort of diagnostics titan, but investors should be encouraged that management is looking at multiple avenues to continue growing the business. (For more, see Where The M&A Action Is, And What's Next.)

Use the Investopedia Stock Simulator to trade the stocks mentioned in this stock analysis, risk free!

Related Articles
  1. Personal Finance

    A Day in the Life of an Equity Research Analyst

    What does an equity research analyst do on an everyday basis?
  2. Mutual Funds & ETFs

    ETF Analysis: PowerShares S&P 500 Downside Hedged

    Find out about the PowerShares S&P 500 Downside Hedged ETF, and learn detailed information about characteristics, suitability and recommendations of it.
  3. Mutual Funds & ETFs

    ETF Analysis: iShares Morningstar Small-Cap Value

    Find out about the Shares Morningstar Small-Cap Value ETF, and learn detailed information about this exchange-traded fund that focuses on small-cap equities.
  4. Mutual Funds & ETFs

    ETF Analysis: ProShares Large Cap Core Plus

    Learn information about the ProShares Large Cap Core Plus ETF, and explore detailed analysis of its characteristics, suitability and recommendations.
  5. Mutual Funds & ETFs

    ETF Analysis: iShares Core Growth Allocation

    Find out about the iShares Core Growth Allocation Fund, and learn detailed information about its characteristics, suitability and recommendations.
  6. Mutual Funds & ETFs

    ETF Analysis: iShares MSCI USA Minimum Volatility

    Learn about the iShares MSCI USA Minimum Volatility exchange-traded fund, which invests in low-volatility equities traded on the U.S. stock market.
  7. Stock Analysis

    Should You Follow Millionaires into This Sector?

    Millionaire investors—and those who follow them—should take another look at the current economic situation before making any more investment decisions.
  8. Professionals

    What to do During a Market Correction

    The market has corrected...now what? Here's what you should consider rather than panicking.
  9. Mutual Funds & ETFs

    ETF Analysis: WisdomTree SmallCap Earnings

    Discover the WisdomTree Small Cap Earnings ETF, a fund with a special focus on small-cap and micro-cap stocks with positive earnings.
  10. Mutual Funds & ETFs

    ETF Analysis: iShares US Regional Banks

    Obtain information and analysis of the iShares US Regional Banks ETF for investors seeking particular exposure to regional bank stocks.
RELATED TERMS
  1. Equity

    The value of an asset less the value of all liabilities on that ...
  2. Profit Margin

    A category of ratios measuring profitability calculated as net ...
  3. Quarter - Q1, Q2, Q3, Q4

    A three-month period on a financial calendar that acts as a basis ...
  4. Debt Ratio

    A financial ratio that measures the extent of a company’s or ...
  5. Price-Earnings Ratio - P/E Ratio

    The Price-to-Earnings Ratio or P/E ratio is a ratio for valuing ...
  6. Net Present Value - NPV

    The difference between the present values of cash inflows and ...
RELATED FAQS
  1. What is the formula for calculating compound annual growth rate (CAGR) in Excel?

    The compound annual growth rate, or CAGR for short, measures the return on an investment over a certain period of time. Below ... Read Full Answer >>
  2. What is the difference between called-up share capital and paid-up share capital?

    The difference between called-up share capital and paid-up share capital is investors have already paid in full for paid-up ... Read Full Answer >>
  3. When does the fixed charge coverage ratio suggest that a company should stop borrowing ...

    Since the fixed charge coverage ratio indicates the number of times a company is capable of making its fixed charge payments ... Read Full Answer >>
  4. Why would a corporation issue convertible bonds?

    A convertible bond represents a hybrid security that has bond and equity features; this type of bond allows the conversion ... Read Full Answer >>
  5. What is the difference between the return on total assets and an interest rate?

    Return on total assets (ROTA) represents one of the profitability metrics. It is calculated by taking a company's earnings ... Read Full Answer >>
  6. How does additional paid in capital affect retained earnings?

    Both additional paid-in capital and retained earnings are entries under the shareholders' equity section of a company's balance ... Read Full Answer >>

You May Also Like

COMPANIES IN THIS ARTICLE
Trading Center
×

You are using adblocking software

Want access to all of Investopedia? Add us to your “whitelist”
so you'll never miss a feature!